|By Marketwired .||
|August 27, 2014 05:00 PM EDT||
YONKERS, NY -- (Marketwired) -- 08/27/14 -- ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that the underwriter of its initial public offering has exercised its over-allotment option in connection with the company's initial public offering of units which closed on August 1, 2014.
Accordingly, effective today, the underwriter has exercised and closed an option to purchase 880,333 additional units at the initial public offering price of $6.00 per unit, less underwriting discounts and expenses. With this exercise, ContraFect's initial public offering totaled 6,880,333 units, with gross proceeds of $41,281,998 (of which $5,281,998 was raised via the exercise of the over-allotment option). The underwriter's over-allotment option is for 900,000 additional units in total.
Maxim Group LLC acted as the sole book-running manager of the offering. The units are listed on the Nasdaq Capital Market and trade under the symbol "CFRXU".
On or prior to September 12, 2014, the units will separate into shares of common stock, Class A warrants and Class B warrants and the component securities will begin trading on the Nasdaq Capital Market as separate securities. The shares of common stock are expected to trade under the symbol "CFRX", the Class A warrants are expected to trade under the symbol "CFRXW" and the Class B Warrants are expected to trade under the symbol "CFRXZ". ContraFect will issue a press release announcing the date such separate trading will begin.
Roth Capital Partners, LLC acted as financial advisor to ContraFect in connection with this offering.
A registration statement relating to the units and the underlying securities has been declared effective by the Securities and Exchange Commission. The offering of the units was made only by means of a prospectus, copies of which may be obtained by contacting Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, or by calling 212-895-3685. The final prospectus also may be obtained at the Securities and Exchange Commission's website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
This press release includes forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to ContraFect's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of ContraFect's management but are subject to significant risks and uncertainties, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the timing for the separation of ContraFect's publicly traded units into their component securities as described herein) may differ from those set forth in the forward-looking statements. Except as required by applicable law, ContraFect expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in ContraFect's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Apr. 29, 2016 07:30 PM EDT Reads: 2,393
Apr. 29, 2016 05:15 PM EDT Reads: 1,678
Apr. 29, 2016 04:30 PM EDT Reads: 1,756
Apr. 29, 2016 04:30 PM EDT Reads: 601
Apr. 29, 2016 03:45 PM EDT Reads: 1,591
Apr. 29, 2016 03:30 PM EDT Reads: 1,649
Apr. 29, 2016 03:15 PM EDT Reads: 1,530
Apr. 29, 2016 03:07 PM EDT Reads: 228
Apr. 29, 2016 03:00 PM EDT Reads: 836
Apr. 29, 2016 02:45 PM EDT Reads: 835
Apr. 29, 2016 02:30 PM EDT Reads: 1,397
Apr. 29, 2016 02:30 PM EDT Reads: 1,396
Apr. 29, 2016 02:00 PM EDT Reads: 826
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
Apr. 29, 2016 02:00 PM EDT Reads: 972
The paradigm has shifted. A Gartner survey shows that 43% of organizations are using or plan to implement the Internet of Things in 2016. However, not just a handful of companies are still using the old-style ad-hoc trial-and-error ways, unaware of the critical barriers, paint points, traps, and hidden roadblocks. How can you become a winner? In his session at @ThingsExpo, Tony Shan will present a methodical approach to guide the holistic adoption and enablement of IoT implementations. This ov...
Apr. 29, 2016 02:00 PM EDT Reads: 1,531